Dr. Benjamin Cooper
Radiation Oncology (Radiation Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 300
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Temple University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Radiation Oncology Physician primary
NY license 284853
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
- Princeton Procure Management, LLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 300
- Services billed
- 2,386
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Calculation of radiation therapy dose | 694 | 131 |
| Ct guidance for insertion of radiation therapy fields | 550 | 65 |
| Design and construction of complex radiation treatment device | 382 | 162 |
| Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | 260 | 40 |
| Radiation treatment management, 5 treatment sessions | 242 | 99 |
| Complex radiation therapy planning | 135 | 126 |
| New patient office or other outpatient visit, 60-74 minutes | 97 | 97 |
| Design and construction of radiation treatment device for high precision radiation therapy | 80 | 73 |
| High precision radiation therapy planning | 75 | 71 |
| 3d radiation therapy planning | 72 | 63 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $3,833 in total to this clinician.
| Janssen Research & Development, LLC | $3,810 |
|---|---|
| Daiichi Sankyo Inc. | $22.69 |
| Consulting Fee | $3,810 |
|---|---|
| Food and Beverage | $22.69 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Nov 3, 2025 | Consulting Fee | $3,810 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $157,745 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer
Janssen Research & Development, LLC - An open-label, phase 1, dose-escalation study to evaluate the safety and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of non-small-cell lung cancer, triple-…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.